PCM
HRMY icon

Prelude Capital Management’s Harmony Biosciences HRMY Stock Holding History

Prelude Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$338K Buy
12,060
+3,900
+48% +$128K 0.03% 660
2025
Q4 		$305K Sell
8,160
-3,826
-32% -$126K 0.02% 787
2025
Q3 		$330K Buy
+11,986
New +$413K 0.03% 686
2025
Q2 		– Sell
-6,920
Closed -$230K – 1145
2025
Q1 		$230K Buy
+6,920
New +$248K 0.02% 849

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Prelude Capital Management's HRMY Position: Q1 2026 in Review

Prelude Capital Management increased its Harmony Biosciences (HRMY) stake by 48% in Q1 2026, buying an estimated $128K and bringing the position to 12,060 shares worth $338K. The position accounts for 0.03% of the portfolio, ranked #660.

Prelude Capital Management first reported a position in HRMY in Q1 2025 and has held it in 4 quarters since. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Prelude Capital Management held 12,060 shares of Harmony Biosciences worth $338K as of Q1 2026.
  • Prelude Capital Management bought 3,900 Harmony Biosciences shares in Q1 2026, an estimated $128K.
  • Harmony Biosciences made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #660 holding.
  • Prelude Capital Management first reported a position in Harmony Biosciences in Q1 2025 and has held it in 4 quarters since.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.